Combination of Azacitidine and Lenalidomide in Myelodysplastic Syndromes or acute Myeloid Leukemia—a wise Liaison?
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Link
http://www.nature.com/articles/leu2013140.pdf
Reference66 articles.
1. Platzbecker U . Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndromes. Seminars in Hematology 2012; 49: 342–349.
2. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223–232.
3. Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J et al. Randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 2012; 30: 2670–2677.
4. Lubbert M, Suciu S, Baila L, Ruter BH, Platzbecker U, Giagounidis A et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate-or high-risk myelodysplastic syndrome (mds) ineligible for intensive chemotherapy: final results of the randomized phase III study of the european organisation for research and treatment of cancer leukemia group and the german mds study group. J Clin Oncol 2011; 29: 1987–1996.
5. Giagounidis AAN. Lenalidomide for del(5q) and non-del(5q) myelodysplastic syndromes. Seminars in Hematology 2012; 49: 312–322.
Cited by 27 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Hypomethylating agent based combinations in higher risk myelodysplastic syndrome;Leukemia & Lymphoma;2019-12-09
2. The Impact of Immune Interventions: A Systems Biology Strategy for Predicting Adverse and Beneficial Immune Effects;Frontiers in Immunology;2019-02-15
3. Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs;Cardiovascular & Hematological Disorders-Drug Targets;2019-01-28
4. Beyond the Edge of Hypomethylating Agents: Novel Combination Strategies for Older Adults with Advanced MDS and AML;Cancers;2018-05-24
5. Current therapy and new drugs: a road to personalized treatment of myelodysplastic syndromes;Expert Review of Precision Medicine and Drug Development;2017-12-27
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3